High response rates for bictegravir or dilutegraver with FTC/TAF for initial HIV therapy | CROI

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Bictegravir (BIC) + FTC/TAF and dolutegravir (DTG) + FTC/TAF both demonstrated high virologic response rates at W24 that were maintained at W48.
  • No treatment-emergent resistance was detected in the BIC+FTC/TAF arm through W48. 

Why this matters

  • Because of their potency and...